302 related articles for article (PubMed ID: 19710504)
1. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
2. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
Mavroudi I; Pyrovolaki K; Pavlaki K; Kozana A; Psyllaki M; Kalpadakis C; Pontikoglou C; Papadaki HA
Leuk Res; 2011 Mar; 35(3):323-8. PubMed ID: 20688394
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
4. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Pathak S; Roth M; Verma A; Steidl U
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Tamari R; Schinke C; Bhagat T; Roth M; Braunschweig I; Will B; Steidl U; Verma A
Leuk Lymphoma; 2014 Dec; 55(12):2901-6. PubMed ID: 24650011
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
[TBL] [Abstract][Full Text] [Related]
10. The new thrombopoietic agenda: impact on leukemias and MDS.
Bussel JB
Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
12. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
Elife; 2021 Jun; 10():. PubMed ID: 34059198
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Fattizzo B; Levati G; Cassin R; Barcellini W
Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
[TBL] [Abstract][Full Text] [Related]
14. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.
Sun H; Tsai Y; Nowak I; Liesveld J; Chen Y
Stem Cell Res; 2012 Sep; 9(2):77-86. PubMed ID: 22683680
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
Serebruany VL; Eisert C; Sabaeva E; Makarov L
Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag for treatment of thrombocytopenia-associated disorders.
Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag in chronic hepatitis C.
Mihăilă RG; Cipăian RC
World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
[TBL] [Abstract][Full Text] [Related]
19. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
